The U.S. Food and Drug Administration has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAFV600 wildtype and BRAFV600 mutation-positive unresectable or metastatic melanoma.
A new kind of gene therapy tested in animals could be safe and effective for human patients with hemophilia B.
Preliminary overall 2015-16 influenza vaccine effectiveness was 59 percent, according to the Centers for Disease Control and Prevention.
The U.S. Food and DrugAdministration approved Merck and Co.’s Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuroniumbromide and vecuronium bromide.
The U.S. Food and Drug Administration granted accelerated approval for pembrolizumab (Keytruda, Merck & Co.) for treatment of patients with advanced (metastatic)
non-small cell lung cancer.
In its Phase I clinical trial, ProMetic Life Sciences successfully completed its first round of IV plasminogen dosing in plasminogen deficiency patients.
The Centers for Medicare and Medicaid Services has published several policies on biosimilars reimbursement.
A recent study discovered a biomarker in chronic inflammatory demyelinating polyneuropathy patients that explains why they don’t respond to intravenous immune globulin therapy.
The U.S. Food and Drug Administration has approved Baxalta’s Adynovate for use in hemophilia A patients aged 12 years and older.
In response to concerns by providers about the ICD-9 to ICD-10 coding system, the Centers for Medicare and Medicaid Services says it will reimburse for incorrectly coded claims for one year past the Oct. 1, 2015, deadline.
Results of a Phase III study show that BAX 111, a highly purified recombinant von Willebrand factor analog manufactured by Baxalta, appeared safe and effective for treatment of bleeding episodes in patients with severe von Willebrand’s disease.
The Centers for Medicare and Medicaid Services has created an interactive online dashboard to allow the public and policymakers to explore the financial burden that high-expense drugs place on the Medicare program and the nation’s seniors.
